Search Within

Eric Smith

Formats
  1. Meeting Abstract (42)
  2. Journal Article (27)
  3. Book Section (3)
  4. Research Letter (2)
  5. Guidelines (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (76)
  2. Department of Medicine (76)
  3. Hematologic Malignancies Research (76)
  4. Hematologic Malignancies, Division of (76)
  5. Myeloma (76)
  6. Survivorship Research (48)

More Groups

People
  1. Sham Mailankody (44)
  2. Carl Landgren (42)
  3. Alexander Lesokhin (38)
  4. Sergio Giralt (38)
  5. Hani Hassoun (36)
  6. Neha Korde (36)

More People

Years
  1. 2025 (1)
  2. 2022 (2)
  3. 2021 (5)
  4. 2020 (13)
  5. 2019 (19)
  6. 2018 (15)

More Years

Publications
  1. Blood (27)
  2. Biology of Blood and Marrow Transplantation (8)
  3. Clinical Lymphoma, Myeloma and Leukemia (7)
  4. Journal of Clinical Oncology (4)
  5. Pocket Oncology (3)
  6. Blood Cancer Discovery (2)

More Publications

Publishers
  1. American Society of Hematology (28)
  2. Elsevier Inc. (16)
  3. Nature Publishing Group (5)
  4. American Association for Cancer Research (4)
  5. American Society of Clinical Oncology (4)
  6. Wolters Kluwer Health | Lippincott Williams & Wilkins (3)

More Publishers

Results (76)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Presalvage international staging system stage and other important outcome associations in CD34(+)-selected allogeneic hematopoietic stem cell transplantation for multiple myelomas
    Journal Article

    Bryant, A. R.; Hilden, P.; Giralt, S.; Chung, D. J.; Maloy, M.; Landau, H.; Landgren, O.; Scordo, M.; Shah, G.; Smith, E. L.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Meeting Abstract

    Eveillard, M.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Smith, E. L.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Korde, N.; Landgren, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft purity with novel induction regimens in multiple myeloma
    Meeting Abstract

    Bal, S.; Landau, H.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Hassoun, H.; Hultcrantz, M.; Korde, N. S.; Lesokhin, A. M.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save